Carregant...

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a negative regulator of T-cell mediated immune responses and is the target of new anti-tumor immunotherapy strategies. Ipilimumab is a fully human, antagonistic monoclonal antibody directed against CTLA-4. Results from preclinical and early clinical trial...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Saenger, Yvonne M., Wolchok, Jedd D.
Format: Artigo
Idioma:Inglês
Publicat: Academy of Cancer Immunology 2008
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935787/
https://ncbi.nlm.nih.gov/pubmed/18198818
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!